Cargando…
Phase 4 Multinational Multicenter Retrospective and Prospective Real-World Study of Nivolumab in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
SIMPLE SUMMARY: In 2020, there were 880,000 new cases and 440,000 deaths attributed to head and neck cancer worldwide. Nivolumab was approved in 2016 in the United States, and 2017 in the European Union and Canada, for use in patients with recurrent/metastatic squamous cell carcinoma of the head and...
Autores principales: | Gogate, Anagha, Bennett, Bryan, Poonja, Zia, Stewart, Grant, Medina Colmenero, Ana, Szturz, Petr, Carrington, Courtney, Castro, Clara, Gemmen, Eric, Lau, Ashley, Carral Maseda, Alberto, Winquist, Eric, Arrazubi, Virginia, Hao, Desiree, Cook, Audrey, Martinez Galan, Joaquina, Ugidos, Lisardo, Fernández Garay, David, Gutierrez Abad, David, Metcalf, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377225/ https://www.ncbi.nlm.nih.gov/pubmed/37509217 http://dx.doi.org/10.3390/cancers15143552 |
Ejemplares similares
-
From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer
por: Martín, Andrés Muñoz, et al.
Publicado: (2018) -
SEOM-TTCC clinical guideline in nasopharynx cancer (2021)
por: Rueda Domínguez, Antonio, et al.
Publicado: (2022) -
SEOM clinical guidelines for the treatment of head and neck cancer (2017)
por: Iglesias Docampo, L. C., et al.
Publicado: (2017) -
A Case of Nivolumab-Induced Myositis
por: Fox, Eric, et al.
Publicado: (2016) -
Multinational democracies /
Publicado: (2001)